Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
4.780
+0.035 (0.74%)
At close: Apr 2, 2025, 4:00 PM
4.699
-0.082 (-1.71%)
After-hours: Apr 2, 2025, 6:26 PM EDT
Company Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.
Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Vipin Garg |
Contact Details
Address: 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 United States | |
| Phone | 240 654 1450 |
| Website | altimmune.com |
Stock Details
| Ticker Symbol | ALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326190 |
| CUSIP Number | 02155H200 |
| ISIN Number | US02155H2004 |
| Employer ID | 20-2726770 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vipin K. Garg Ph.D. | President, Chief Executive Officer and Director |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer |
| Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer |
| Andrew Shutterly M.S. | Principal Financial and Accounting Officer and Corporate Controller |
| Bertrand Georges Ph.D. | Chief Technology Officer |
| Tony Blandin B.S. | Vice President of Quality and Compliance Management |
| Raymond M. Jordt M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | EFFECT | Notice of Effectiveness |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 27, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Dec 11, 2024 | 8-K | Current Report |